AUVIP
10/14/26

Applied UV (AUVIP)

Wednesday
8:26 AM
ThesisGrowing demand for health and safety solutions and strategic partnerships are enhancing the company's growth outlook.

Revenue Outlook

★ Analysts see FY2024 revenue reaching $46M — +13.0% growth in a single year.

The Bull Case for Growth

  1. 01Recent partnerships with major hospital networks could increase market penetration by 25% over the next year.
  2. 02New regulatory approval for a next-gen UV device expected to enhance efficacy by 40%.
  3. 03Increased demand for disinfection solutions post-COVID-19 is driving a 50% increase in inquiries from potential clients.
  4. 04Potential expansion into European markets could unlock an additional $10M in revenue.
  5. 05Increased focus on health and safety in public spaces
  6. 06Growth in the healthcare sector driven by technological advancements
  7. 07Adoption rates of UV disinfection technology in healthcare facilities
  8. 08Regulatory approvals for new products
FY2023 Snapshot
NI Growth
+40.1%
EPS
$-35.63

AUVIP Chart

0.00.00.00.00.00.00AUVIP Daily0.00Jun '26Jul '26Jul '26Jul '26

My Notes

  • "Our technology is becoming essential in a world that prioritizes health and safety."
  • Moat: The proprietary nature of Applied UV's technology provides a strong competitive advantage in a growing market.
  • growth - Investors seeking exposure to innovative health and safety technologies.
  • Higher interest rates could increase financing costs for expansion and R&D, potentially impacting profitability and valuation multiples.
  • Watch on earnings: Adoption rates of UV technology in hospitals, Gross margin trends, Regulatory approval timelines.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $46M to $46M as recent partnerships with major hospital networks could increase market penetration by 25% over the next year.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.